Lotus Clinical Research

Lotus Clinical Research is a clinical research organization specializing in neuroscience and metabolic disease development. The organization operates as a unified entity with Evolution Research Group (ERG), providing integrated CRO services and direct access to a network of 20 wholly-owned US research units, over 400 beds, nine surgical centers, and multiple Phase I units.

Clinical Expertise & Leadership

The Lotus-ERG team includes 47 MDs and 12 PhDs/PsyDs providing scientific and clinical leadership across trials. The organization has supported more than 3,400 studies and contributed to 32 FDA approvals since 2023, representing 27% of all US drug approvals. A dedicated Scientific Leadership Team reviews protocols at bid stage to assess and mitigate study risks, with team members assigned to every trial.

Therapeutic Focus

• Neuroscience: Deep experience across the disease spectrum, including psychiatry, neurology, Alzheimer's disease, sleep disorders, pain management, and addiction medicine.
• Metabolic Disease: Specialized capabilities in diabetes, MASH/MAFLD, and obesity research, with access to well-equipped sites featuring FibroScan, MRI, and biopsy capabilities.

Operational Advantages

Common ownership with ERG enables rapid study startup and operational efficiency. Many site-initiation activities (contracting, legal) are pre-established, allowing prioritized sponsor study activation. The organization supports clinical research from first-in-human through late-phase development with global reach.